Get email updates from SABCSMeetingNews.org
Subscribe to get regular news updates from SABCS.org and SABCS Meeting News.
DECEMBER 6–10, 2022
Henry B. Gonzalez Convention Center
|
San Antonio, TX
-
Studies looking at impact of race on breast cancer severity and outcomes presented at #SABCS21
Friday’s General Session included two studies into race as a factor in the incidence, severity, and treatment outcomes of breast cancer.
-
AACR Outstanding Investigator Award: Precision medicine a work in progress
Fabrice André, MD, PhD, received this year’s AACR Outstanding Investigator Award for Breast Cancer Research for his work helping to establish the concept of using real-time, high-throughput genomic analysis of cancer biopsies to identify potential therapeutic targets.
-
Special session explores how to build trust in science, healthcare
Lori Wilson, MD, and Charles Perou, PhD, gave keynote presentations during a special session focused on advancing health equity through building trust and improving access to care and clinical trials.
-
Data from PADA-1 and PHOEBE trials presented on Thursday at #SABCS21
Thursday’s General Session included findings from a study looking at fulvestrant plus palbociclib for HR+ breast cancer and results of a study of pyrotinib plus capecitabine for previously treated HER2+ metastatic breast cancer.
-
AACR distinguished lecturer discusses cell cycle discoveries leading to targeted therapies
Helen M. Piwnica-Worms, PhD, discussed her journey from basic research to translational trials during the 2021 AACR Distinguished Lectureship in Breast Cancer Research on Thursday.
-
Debate will tackle 1-week versus 3-week whole breast radiation for early-stage breast cancer
During a debate this morning, Charlotte Coles, MBChB, PhD, will present the “Pro” argument, and Julia White, MD, will present the “Con” argument on the adoption of a new schedule for whole breast radiotherapy.
-
Results from EMERALD trial and key findings from PI3K pathway inhibitor study presented at #SABCS21
Wednesday’s General Session featured new data about the oral SERD elacestrant and the effect of tamoxifen on uterine cancer risk.
-
McGuire Award Lecture: Moving to precision care in breast cancer
Olufunmilayo I. Olopade, MD, FAACR, recounted her lifelong journey through breast cancer genomics during the William L. McGuire Memorial Lecture on Wednesday.
-
Regulatory session covers latest breast cancer treatment approvals
A special session on Wednesday reviewed the Food and Drug Administration’s recent approval of pembrolizumab for neoadjuvant and adjuvant treatment, and abemaciclib in the adjuvant setting.
-
Clinical Science Forum to focus on breast cancer-specific use of ablation for oligometastatic disease
The forum, moderated by Steven Chmura, MD, PhD, will include two state-of-the-art presentations covering what is currently known about ablation of oligometastatic disease in breast cancer.